AcelRx Pharmaceuticals (ACRX)
AcelRx Pharmaceuticals Revenues: 0.624M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ACRX Revenues Rankings
| Overall | 1st percentile | 4343 of 4425 |
| Sector | 8th percentile | 429 of 470 in Healthcare |
| Industry | 0th percentile | 20 of 20 in Drug Manufacturers - Major |
ACRX Revenues Range, Past 5 Years
| Minimum | 0.04M | Jun 2011 |
| Maximum | 0.624M | Dec 2011 |
| Average | 0.3573M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these ACRX related companies
ACRX News
AcelRx Pharmaceuticals Receives Two Notices of Allowance for Small-Volume Oral Transmucosal Dosage Forms
Apr 11, 7:30AM PR Newswire
Apr 11, 7:30AM PR Newswire
AcelRx Pharmaceuticals (ACRX) Posts Narrower than Expected Q4 Loss of 33c/Share
Mar 20, 7:36AM Street Insider
Mar 20, 7:36AM Street Insider
AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results
Mar 20, 7:30AM PR Newswire
Mar 20, 7:30AM PR Newswire
AcelRx Pharmaceuticals to Present at Two Near-Term Health Care Conferences
Feb 21, 7:30AM PR Newswire
Feb 21, 7:30AM PR Newswire
AcelRx Announces its ARX-01 Phase 3 Program Expected to Start Late Q1 or Early Q2 2012
Jan 31, 7:31AM Benzinga
Jan 31, 7:31AM Benzinga
AcelRx Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health Care Conference
Nov 23, 7:30AM PR Newswire
Nov 23, 7:30AM PR Newswire
AcelRx Pharmaceuticals to Present at Two Healthcare Investor Conferences in the Second Half of September
Sep 15, 7:30AM PR Newswire
Sep 15, 7:30AM PR Newswire
AcelRx Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
Sep 09, 7:30AM PR Newswire
Sep 09, 7:30AM PR Newswire
AcelRx Pharmaceuticals to Present at the Southern California Investor Conference
Aug 25, 7:30AM PR Newswire
Aug 25, 7:30AM PR Newswire
Canaccord Genuity Reiterates a 'Buy' on AcelRx Pharmaceuticals (ACRX); ARX-01's Phase 3 Study to Commence by Q4 in H1/12
Aug 12, 8:18AM Street Insider
Aug 12, 8:18AM Street Insider
AcelRX Pharmaceuticals on track to initiate first ARX-01 Phase 3 clinical trial
Aug 11, 7:49AM FlyOnTheWall
Aug 11, 7:49AM FlyOnTheWall
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACRX | 3.53 | +0.07 | +2.17% | 69.08M |
| ACPW | 0.7397 | -0.00 | -0.04% | 70.19M |
| ACET | 8.25 | +0.03 | +0.36% | 221.10M |
| ACE | 73.18 | -0.06 | -0.08% | 24.67B |
| ACCU | 22.92 | +0.00 | +0.00% | |
| ACCL | 7.68 | -0.05 | -0.65% | 412.72M |
| ACC | 43.97 | -0.09 | -0.20% | 3.284B |
| ACAT | 36.10 | -0.24 | -0.66% | 456.66M |
| ACAS | 9.17 | -0.02 | -0.22% | 3.063B |
| ABVT | 83.29 | -0.03 | -0.04% | 2.188B |
